Palonosetron (Helsinn).

  title={Palonosetron (Helsinn).},
  author={Georg Stacher},
  journal={Current opinion in investigational drugs},
  volume={3 10},
  • Georg Stacher
  • Published 2002 in Current opinion in investigational drugs
Palonosetron, a selective 5-HT3 receptor antagonist, is being developed by Helsinn for the potential treatment of chemotherapy-induced nausea and vomiting. By 1999, it was in phase III trials, and as of May 2002, an NDA filing was scheduled for the third quarter of 2002. 

From This Paper

Topics from this paper.


Publications citing this paper.

Similar Papers

Loading similar papers…